About InVivoMAb anti-mouse NKG2A/C/E

The 20D5 monoclonal antibody reacts with mouse NKG2A, NKG2C, and NKG2E also known as CD159a, CD159c, and CD159e respectively. The NKG2 receptors belong to a family of C-type lectin-like receptors that form heterodimers with CD94. NKG2/CD94 heterodimeric complexes are primarily expressed on NK cells and NKT cells. NKG2 receptors are also expressed on CD8⁺ T cells activated in vivo and in vitro. NKG2/CD94 heterodimeric complexes recognize Qa-1, a nonclassical MHC class I antigen, presenting the Qdm peptide. CD94/NKG2 heterodimers on NK cells transduce signals after ligand binding. NKG2A is thought to transduce inhibitory signals, while NKG2C and NKG2E transduce stimulatory signals. Blocking NKG2A signaling has been shown to promote anti-tumor immunity in murine tumor models by enhancing the activity of both T and NK cells. For this reason, NKG2A targeting is being explored as a novel immune checkpoint inhibitory therapy for treating human cancers.

*An engineered recombinant mouse variant of the rat IgG2a anti-mouse NKG2A/C/E (clone 20D5) antibody with mouse IgG constant domains has been shown to block NKG2A signals in vivo in murine tumor models. BE0321 is the original 20D5 clone with rat IgG constant domains.